CRP and non-small cell lung carcinoma: We and others have recently shown that the CRP flare-response phenomenon, which is defined by an early CRP increase after initiation of ICI followed by a decrease below baseline, predicts ICI response across entities in metastatic renal cell carcinoma, urothelial cancer, and non-small cell lung cancer (NSCLC) (2-5).